Genprex Company Insiders

Genprex's latest congressional trading

Genprex Management Team Effectiveness

The company has return on total asset (ROA) of (2.0741) % which means that it has lost $2.0741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.123) %, meaning that it created substantial loss on money invested by shareholders. Genprex's management efficiency ratios could be used to measure how well Genprex manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -4.38 in 2026. Return On Capital Employed is likely to rise to -14.28 in 2026. At this time, Genprex's Net Tangible Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to rise to 0.13 in 2026, whereas Total Assets are likely to drop slightly above 4.5 M in 2026. Common Stock Shares Outstanding is likely to drop to about 68.5 K in 2026. Net Loss is likely to rise to about (16.8 M) in 2026Roughly 97.27 (percent) of Genprex outstanding shares are held by general public with 1.17 % owned by insiders and only 1.56 pct. by outside corporations. On January 8, 2026, Representative Tim Moore of US Congress acquired under $15k worth of Genprex's common stock. Some institutional investors establish a significant position in stocks such as Genprex in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Genprex, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Genprex Workforce Comparison

Genprex Insider Trading History

Genprex Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Genprex often depends on how effective the management is. Genprex management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Genprex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Genprex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Genprex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genprex. Check Genprex's Beneish M Score to see the likelihood of Genprex's management manipulating its earnings.

When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.